Stockreport

Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

Qualigen Therapeutics, Inc.  (QLGN) 
PDF JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement [Read more]